Clinical trials
Graft Versus Host Disease clinical trials
Below are recruiting graft versus host disease clinical trials, each written for real people, not researchers. We’re tracking 121 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07253259RecruitingEarly Phase 1
Cell therapy for hard-to-treat chronic graft-versus-host disease
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06186804Enrolling by invitationPhase 2
Study of ABSK021 for chronic graft-versus-host disease
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07029958RecruitingPhase 4
Transplant protocol for EBV-related T/NK lymphoproliferative disease
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
BeijingAges birth–18 years - NCT06880419RecruitingPhase 2
Anti-CD25 antibody to prevent graft-versus-host disease in high-risk adults
This trial tests whether an antibody called anti-CD25 can help prevent a serious side effect (graft-versus-host disease) in adults getting a stem cell transplant for blood disorders. It is for people considered high-risk based on a special scoring model.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT06904599RecruitingPhase 2
Testing hCG for acute GVHD after a stem cell transplant
This study tests if a hormone called hCG can help treat moderate-to-severe graft-versus-host disease (GVHD) after a stem cell transplant. It is for adults who have recently developed GVHD and need steroids, but have not been on high-dose steroids for long.
Monterrey, Nuevo LeónAges 18 years+ - NCT06973668RecruitingPhase 2
Comparing drug combos to prevent graft versus host disease after stem cell transplant
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
Houston, TexasAges 65–75 - NCT07025538RecruitingPhase 1
Preventing chronic graft-versus-host disease with ruxolitinib
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
Duarte, CaliforniaAges 18 years+ - NCT07325253RecruitingPhase 2
PET scan study for chronic graft versus host disease
This trial uses a special PET scan to see if we can better understand chronic graft versus host disease (cGVHD), a complication after a stem cell transplant. The study is for people with joint stiffness caused by cGVHD, and it may help doctors find new ways to manage symptoms.
Houston, TexasAges 18 years+ - NCT00092235Recruiting
Understanding chronic graft-versus-host disease outcomes
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
Bethesda, MarylandAges 1–120 - NCT06660355RecruitingPhase 2
Comparing two medicines for chronic graft-versus-host disease
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Miami, FloridaAges 18 years+ - NCT07724873RecruitingPhase 1/Phase 2
Withaferin A to prevent GVHD after stem cell transplant
This study tests a natural compound called Withaferin A (from ashwagandha) to see if it helps prevent graft-versus-host disease (GVHD) after a stem cell transplant. The goal is to reduce the risk of transplant complications.
Navi Mumbai, MaharashtraAges 18 years+ - NCT06991361RecruitingPhase 1
Expanded immune cells and low-dose IL-2 for chronic GVHD
This trial tests whether giving special immune cells (regulatory T cells) grown in a lab, along with a low dose of interleukin-2, can help people with chronic graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body.
Boston, MassachusettsAges 2 years+ - NCT07235501Recruiting
Studying immune cells in chronic GVHD after stem cell transplant
This study looks at immune cells in the blood and tissues of people who have had a stem cell transplant. It aims to understand chronic graft-versus-host disease (GVHD), a common complication, so doctors can better detect and treat it.
Duarte, CaliforniaAges 7 years+ - NCT07708987RecruitingPhase 2
Withaferin-A for steroid-resistant graft-versus-host disease
This trial tests a plant-based medicine, Withaferin-A, in people whose graft-versus-host disease (GVHD) after a stem cell transplant has not responded to steroid treatment. GVHD is a condition where donated immune cells attack the body; this study aims to see if Withaferin-A can help control it.
Navi Mumbai, MaharashtraAges 12–65 - NCT06247150Recruiting
Study of immune cells in graft-versus-host disease after stem cell transplant
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
PessacAges 18 years+ - NCT03779854RecruitingPhase 2
Preventing graft-versus-host disease in kids after stem cell transplant
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Los Angeles, CaliforniaAges 6 months–26 years - NCT03818334RecruitingPhase 2/Phase 3
Cyclophosphamide after transplant for blood cancer without sibling donor
This trial studies giving cyclophosphamide after a stem cell transplant when there is no matched sibling donor, but a well-matched unrelated donor is available. It aims to improve outcomes for people with blood cancers undergoing this transplant.
São Paulo, São PauloAges 1–75 - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT04337515Recruiting
Study of a new method to prepare stem cell transplants
This feasibility study tests a technique called CLINIMACS to reduce certain immune cells (alpha/beta T-cells) before a stem cell transplant. It may help make the transplant safer and better controlled, but this is an early-stage feasibility test.
San Francisco, CaliforniaAges Up to 30 years - NCT04380740RecruitingPhase 2
Longer vs shorter abatacept doses to prevent graft-versus-host disease
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Duarte, CaliforniaAges 2 years+ - NCT04660487Recruiting
How diet carbs affect GVHD after bone marrow transplant
This study looks at whether certain types of gut carbohydrates (called FODMAPs) are linked to graft-versus-host disease (GVHD) after a bone marrow transplant. It may help doctors understand how diet could influence symptoms and outcomes for people with specific blood cancers.
Suzhou, JiangsuAges 18–60 - NCT04710576RecruitingPhase 2
Axatilimab for chronic graft-versus-host disease
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Birmingham, AlabamaAges 2 years+ - NCT04745221Recruiting
Fecal microbes therapy to help prevent graft-versus-host disease
This trial studies a treatment made from donor gut microbes to help prevent a common complication after a transplant called acute graft-versus-host disease (aGVHD). It may help by improving the balance and variety of gut bacteria during recovery after haploidentical transplant.
Suzhou, JiangsuAges 18–60
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for graft versus host disease?
- Yes. Clin2 currently lists 121 recruiting graft versus host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a graft versus host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.